Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06047574
Recruiting Observational

Multidisciplinary Diagnosis and Treatment of Polycystic Ovary Syndrome

NCT06047574 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai 10th People's Hospital
Phase
Observational
Started
2023-09-18
Last updated
2026-03-09

Condition(s) studied

Polycystic Ovary Syndrome

Investigational drug(s) / intervention(s)

This study does not involve any interventions

This study does not involve any interventions: This study does not involve any interventions

Study summary

The investigators collected clinical data and serum samples of patients with polycystic ovary syndrome (PCOS) in this study, used statistical software such as SPSS for date analysis, and used experimental techniques such as ELISA and flow cytometry to detect serum samples, aiming to explore the relationship between the body anthropometry, skin conditions, psychosomatic status, diet, sleep, exercise, glucose and lipid metabolism, gonadal hormones, and body fat distribution in patients with polycystic ovary syndrome, and to discovery new biomarkers. Multidisciplinary exploration of the mechanisms of disease occurrence and development, the establishment of a PCOS multicenter, multidisciplinary and multidimensional clinical research database, combined with the established statistical analysis strategy for big data and analysis, to promote the realization of more accurate personalized medicine.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Female aged 18- 45; Exclusion Criteria: * Female patients younger than 18 years old or older than 45 years old; * Ovulatory disorders caused by premature ovarian failure, pituitary amenorrhea, hypothalamic amenorrhea, and thyroid dysfunction; * Congenital adrenal hyperplasia, reservoir Hin syndrome, hyperprolactinemia, adrenal tumors and other diseases that cause hyperandrogenism; * Abnormal liver or renal function((≥ 3 times of the upper limit of normal range) * Type 1 diabetes, single gene mutation diabetes, or pancreatic damage Diabetes or other secondary diabetes caused by diabetes; * History of malignant tumors; * Severe infection, severe anemia, neutropenia and other systemic chronic diseases; * Undergo total hysterectomy or ovarian adnexectomy; * Mental illness, dementia or other cognitive behavioral problems; * Use hypoglycemic drugs that may affect insulin resistance and androgen levels in the last 3 months, including thiazolidinediones, metformin, SGLT-2, and acarbose and GLP-1RA and other drugs; * Use letrozole, clomiphene, oral contraceptives, glucocorticoids, gonadotropins, gonadotropin-releasing hormone agonists, anti-androgens (spironolactone, Cyproterone acetate, flutamide, etc.) and other drugs for the treatment of PCOS.

Primary outcome measure(s)

  • Fibrinogen-like-protein 1 (FGL1) — baseline
    Fibrinogen-like-protein 1 (FGL1), is a novel hepatokine that plays an important role in hepatic steatosis, insulin resistance and obesity. There is no maximum or minimum value for this parameter and the higher scores mean a worse outcome.

Trial sites (1)

FacilityCityRegionStatus
Department of Endocrinology, Shanghai Tenth People's Hospital Shanghai Shanghai Municipality Recruiting

More Shanghai 10th People's Hospital trials in China

Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease Active, not recruiting
Intervention Study on Digital Health Management Starting soon
Assessment of the Effects and Safety of Spermidine Supplementation on Blood Lipids and Body Weight in Overweight or Obese Individuals With Hyperlipidemia Recruiting
Efficacy and Safety of Renal Denervation on Isolated Diastolic Hypertension Starting soon
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease Recruiting

Other trials for the same condition

Study of Acupuncture to Control Weight and Improve Pregnancy Rates in Overweight/Obese PCOS Patients Starting soon
Multimodal Ocular Diagnosis-Guided Precision Acupuncture and Lifestyle Intervention for PCOS Recruiting
Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity Starting soon
Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome Recruiting
Clinical Trial of Anovulatory Infertility Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06047574 on ClinicalTrials.gov ↗ ← All trials in China